ProAxsis Announced A Global Licensing Agreement With The Collaboration Of The University Of Geneva And The University Hospital Of Geneva On A Higly Novel Assay For Cathespin K-dependent Periostin Cleavage Product As A Biomarker Of Bone Fragility Related To Disorders Such As Osteoporosis. - ProAxsis

ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis.

WP_Developer

November 11, 2022

Recent Posts

ProAxsis attends The Bio International Convention June 5-8, 2023

American Thoracic Society Annual Meeting Washington DC, 19-24 May 2023

November 11, 2022

Association of Medical Diagnostics Manufacturers IVD Regulatory Meeting Bethesda, MD 19-20 April,2023

November 11, 2022

Have Any Questions?

Categories

PR8

November 11, 2022

Share This :